Strainsforpains EBYH (OTC: EBYH), Collaborates with Mt. Sinai Hospital in New York City and Johns Hopkins in Baltimore to Merge Advanced AI Data Integrations and Interactions Into Its Proprietary Healthcare APP for Instant Multiple Indications and Critical Ailments Professional Analytics
Strainsforpains (OTC: EBYH) announces collaboration with Mt. Sinai Hospital in New York City and Johns Hopkins in Baltimore to integrate advanced AI data into its proprietary cannabinoid healthcare app. The partnership aims to enhance instant analytics for multiple indications and critical ailments. CEO Simon Shainberg emphasizes the importance of this collaboration in gathering critical data and improving patient usage through AI integration.
The company has developed proprietary algorithms for healthcare professionals to analyze patient data and predict optimal cannabis products and dosages. Strainsforpains EBYH reported annual sales exceeding $300,000 in 2024 with just one product and plans to expand its offerings with AI medical intelligence. The company is also partnering with Cannabis Science to expand its patient outcome list and apply AI technology to critical ailment drugs and therapeutic medicines.
Strainsforpains (OTC: EBYH) annuncia una collaborazione con Mt. Sinai Hospital a New York City e Johns Hopkins a Baltimora per integrare dati avanzati di intelligenza artificiale nella sua app sanitaria proprietaria basata sui cannabinoidi. L'obiettivo della partnership è migliorare le analisi istantanee per molteplici indicazioni e malattie critiche. Il CEO Simon Shainberg sottolinea l'importanza di questa collaborazione per raccogliere dati fondamentali e migliorare l'uso da parte dei pazienti grazie all'integrazione dell'IA.
La società ha sviluppato algoritmi proprietari per i professionisti della salute per analizzare i dati dei pazienti e prevedere i prodotti e i dosaggi di cannabis ottimali. Strainsforpains EBYH ha riportato vendite annuali superiori a $300.000 nel 2024 con un solo prodotto e prevede di espandere la propria offerta con intelligenza medica basata sull'IA. L'azienda sta anche collaborando con Cannabis Science per ampliare la sua lista di risultati per i pazienti e applicare la tecnologia AI ai farmaci per malattie critiche e alle medicine terapeutiche.
Strainsforpains (OTC: EBYH) anuncia una colaboración con Mt. Sinai Hospital en la ciudad de Nueva York y Johns Hopkins en Baltimore para integrar datos avanzados de inteligencia artificial en su aplicación de atención médica de cannabinoides. La asociación tiene como objetivo mejorar el análisis instantáneo para múltiples indicaciones y enfermedades críticas. El CEO Simon Shainberg destaca la importancia de esta colaboración para recopilar datos esenciales y mejorar el uso por parte de los pacientes a través de la integración de IA.
La compañía ha desarrollado algoritmos propietarios para que los profesionales de la salud analicen los datos de los pacientes y prevean los productos y dosificaciones de cannabis óptimos. Strainsforpains EBYH reportó ventas anuales que superan los $300,000 en 2024 con solo un producto y planea expandir su oferta con inteligencia médica basada en IA. La empresa también se está asociando con Cannabis Science para ampliar su lista de resultados para pacientes y aplicar tecnología de IA a medicamentos para enfermedades críticas y medicamentos terapéuticos.
Strainsforpains (OTC: EBYH)는 뉴욕의 Mt. Sinai Hospital와 볼티모어의 Johns Hopkins와 협력하여 자사의 독점적 cannabinoid 헬스케어 앱에 고급 AI 데이터를 통합한다고 발표했습니다. 이 파트너십의 목표는 여러 질환과 중증 질환에 대한 즉각적인 분석을 향상시키는 것입니다. CEO Simon Shainberg는 AI 통합을 통해 중요한 데이터를 수집하고 환자 사용을 개선하는 데 있어 이 협력의 중요성을 강조합니다.
회사는 의료 전문가들이 환자 데이터를 분석하고 최적의 대마초 제품 및 용량을 예측할 수 있도록 독점 알고리즘을 개발했습니다. Strainsforpains EBYH는 2024년에 단일 제품으로 30만 달러 이상의 연간 매출을 보고했으며 AI 의료 인텔리전스를 통해 제품을 확장할 계획입니다. 이 회사는 또한 Cannabis Science와 협력하여 환자 결과 목록을 확대하고 중병 약품 및 치료제에 AI 기술을 적용할 예정입니다.
Strainsforpains (OTC: EBYH) annonce une collaboration avec Mt. Sinai Hospital à New York et Johns Hopkins à Baltimore pour intégrer des données avancées d'intelligence artificielle dans son application de santé cannabique propriétaire. Le partenariat vise à améliorer l'analyse instantanée pour plusieurs indications et maladies critiques. Le PDG Simon Shainberg souligne l'importance de cette collaboration pour recueillir des données essentielles et améliorer l'utilisation par les patients grâce à l'intégration de l'IA.
La société a développé des algorithmes propriétaires permettant aux professionnels de santé d'analyser les données des patients et de prédire les produits de cannabis et les dosages optimaux. Strainsforpains EBYH a enregistré des ventes annuelles dépassant 300 000 USD en 2024 avec un seul produit et prévoit d'élargir son offre avec de l'intelligence médicale basée sur l'IA. L'entreprise s'associe également à Cannabis Science pour élargir sa liste de résultats pour les patients et appliquer la technologie IA aux médicaments pour maladies critiques et aux traitements thérapeutiques.
Strainsforpains (OTC: EBYH) gibt eine Zusammenarbeit mit dem Mt. Sinai Hospital in New York City und Johns Hopkins in Baltimore bekannt, um fortschrittliche KI-Daten in ihre proprietäre cannabinoidbasierte Gesundheits-App zu integrieren. Ziel der Partnerschaft ist es, die sofortige Analyse für multiple Indikationen und kritische Erkrankungen zu verbessern. CEO Simon Shainberg betont die Bedeutung dieser Zusammenarbeit zur Sammlung wichtiger Daten und zur Verbesserung der Nutzung durch Patienten mittels KI-Integration.
Das Unternehmen hat proprietäre Algorithmen entwickelt, mit denen Gesundheitsdienstleister Patientendaten analysieren und optimale Cannabisprodukte sowie Dosierungen vorhersagen können. Strainsforpains EBYH berichtete im Jahr 2024 über einen Jahresumsatz von mehr als 300.000 USD mit nur einem Produkt und plant, sein Angebot mit medizinischer KI zu erweitern. Zudem arbeitet das Unternehmen mit Cannabis Science zusammen, um die Ergebnissliste für Patienten zu erweitern und KI-Technologie auf Medikamente für kritische Erkrankungen sowie therapeutische Mittel anzuwenden.
- Collaboration with prestigious institutions Mt. Sinai and Johns Hopkins for AI data integration
- Developed proprietary algorithms for patient data analysis and cannabis product recommendations
- Achieved annual sales exceeding $300,000 in 2024 with a single product
- Plans to expand product offerings with AI medical intelligence
- Partnership with Cannabis Science to expand patient outcome list and apply AI technology to critical ailment drugs
- None.
NEW YORK, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Strainsforpains, Inc. fka/ E-Buy Home, Inc. (OTC: EBYH), a leader in the health and wellness sector for 17 years, is proud to announce its collaboration with renowned Institutions Mt. Sinai in New York City and Johns Hopkins in Baltimore, MD to merge Advanced AI Data Integrations and Interactions into its Proprietary Cannabinoid Healthcare APP, for instant multiple indications and critical ailments professional analytics.
"Working with renowned institutions such as Mt. Sinai in New York City and Johns Hopkins in Baltimore, immediately gives us an enormous leg up in gathering critical data and patient usage for the Advanced AI integration. By making our APP even more immersive and interactive we are bringing usability levels much higher and the professional patient data analytics output much faster for advanced treatment of all categorized critical ailments and therapeutic medicines”, stated CEO Simon Shainberg.
Mr. Shainberg continued, “We aspire to become a major player in AI medical data integrations in order to close in on the medical information divide between the patients and hospitals. In this rapidly advancing technology age, we are in stride and ahead of the curve by providing real-time AI-integrated tools to assess categorized ailments, patient information, and outsources professionally. We have already begun using pain management in the cannabinoid market to prove and expand our integrated AI healthcare patient educational tools in North America.”
Strainsforpains EBYH, has developed proprietary algorithms that enable healthcare professionals to analyze patient data effectively, predicting optimal cannabis products and dosages for individual patient outcomes. Our partnership with Cannabis Science expands our patient outcome list extensively and we look forward to applying our AI technology to their extensive list of critical ailment drugs and therapeutic medicines.
Strainsforpains EBYH, has achieved remarkable sales, exceeding
Several special events will be announced for 2025, including the ‘1-Million Strong Killing Cancers, VIP Fundraiser Event, Presented by … Strainsforpains (OTC: EBYH)’. This event is intended to encourage celebrities to raise
Strainsforpains EBYH intends to help promote the 1-Million Strong Cannabis Science Cancer Killing Fundraiser to enhance its AI medical technology offerings and expand its product distribution channels via broadcast television coverage and online streaming platforms. The live event series will include a Fashion Show and Concert, within a live MMA Spectacular Event series. This is a VIP fundraiser, designed to drive awareness worldwide.
"Our goal is to create effective natural products that address health issues without relying on pharmaceuticals and drive global awareness through high-profile live events," said Shainberg. The company's unique extracts have undergone rigorous scientific evaluation, contributing to peer-reviewed research that reveals potential benefits in enhancing human longevity. As AI accelerates drug discovery, Strainsforpains is excited to collaborate with oncologists and pain management specialists, significantly reducing the time required to bring new treatments to market. "These developments illustrate the potential of AI to transform pain management and cancer treatment, ultimately improving patient outcomes and quality of care," added Shainberg.
About Strainsforpains, Inc., (OTC: EBYH) fka/ E-Buy Home Inc. Strainsforpains is progressing towards completing its Audit to become fully reporting, change its symbol, creating the revenues and asset base for a NASDAQ Uplisting. “Our company is very involved, and has been for a long time, in the health and wellness space,” said Simon Shainberg, CEO of Strainsforpains, Inc. Strainsforpains, Inc. is an innovative healthcare data technology Company located in New York, N.Y. The Company’s objectives are to provide doctors, nurses, dispensaries, and patients access to an APP that will allow for an advanced determination of comparison of strains or brands of cannabis combinations with major illnesses, in a user-friendly manner. Furthermore, the proprietary app incorporates advanced artificial intelligence, collaborating with pain management departments at hospitals and health care professionals. The app integrates artificial intelligence to expand the selection of cannabis varietals, positioning itself as a leading educational tool for pain management operations at hospitals and with doctors specializing in pain relief. Mr. Shainberg is a member of the prestigious International Cannabinoid Research Society, https://icrs.co/.
Safe Harbor Statement: Statements in this press release that are not historical fact may be deemed forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
Although Strainsforpains, Inc. believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, Strainsforpains, Inc. is unable to give any assurance that its expectations will be attained. Investors are cautioned that any such forward- looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Strainsforpains, Inc.’s ability to control, and those actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in Strainsforpains, Inc. filings with the Securities and Exchange Commission and OTC Markets.
**Media Contact:**
Simon Shainberg
President & CEO
simon@strainsforpains.com
347-218-0844
244 Fifth Avenue, Suite S242
New York, N.Y. 10001
www.strainsforpains.com
https://www.facebook.com/profile.php?id=100071016855607
https://twitter.com/strainsforpains
https://www.instagram.com/strains_for_pains/
https://www.linkedin.com/company/strainsforpains/?viewAsMember=true
https://www.youtube.com/watch?v=E-lftNrcFLk
1-Million Strong Killing Cancers, VIP Fundraiser
Cannabis Science Inc.
Mr. Raymond C. Dabney
President & CEO
raymond.dabney@cannabisscience.com
+1.778.288.1389
https://www.icannabinoid.com/
https://www.cannabisscience.com/
https://www.americanstatesuniversity.com/
https://www.linkedin.com/in/raymond-c-dabney-6970471/
FAQ
What is the purpose of Strainsforpains EBYH's collaboration with Mt. Sinai and Johns Hopkins?
How much revenue did Strainsforpains EBYH (OTC: EBYH) generate in 2024?
What are Strainsforpains EBYH's plans for product expansion?
How does Strainsforpains EBYH's proprietary algorithm benefit healthcare professionals?
